StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Protagonist Therapeutics's price to book ratio was 10.4× on Nov 11, 2026, against 8.7× a year earlier. Over the last 5 years it ranged from 1.3× to 13.4×, with a median of 4.7×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202610.4×+1.9
2025Dec 31, 20258.5×+4.1
2024Dec 31, 20244.3×−0.1
2023Dec 29, 20234.4×+2.2
2022Dec 30, 20222.2×−2.7
2021Dec 31, 20214.9×+0.5
2020Dec 31, 20204.4×+2.4
2019Dec 31, 20192.0×+0.7
2018Dec 31, 20181.3×−4.8
2017Dec 29, 20176.1×+2.3
2016Dec 30, 20163.8×–

More Protagonist Therapeutics figures

See a number that looks wrong?